Special Issue "Forkhead-Box (Fox)O Family Transcription Factors in Cancer"
Deadline for manuscript submissions: 15 June 2024 | Viewed by 131
Interests: growth factor signaling in solid tumors and metastasis; growth factor/steroid hormone crosstalk in hormone-dependent tumors; growth factors signaling proteins as markers of breast cancer progression; role of forkhead-box transcription factor 3a (FoxO3a) in the tumorigenesis and progression of breast cancer; mechanisms of resistance to endocrine therapy in breast cancer; multifunctional mesoporous silica nanoparticles as innovative devices for targeted therapy
Interests: role of the androgen receptor in hormone-dependent tumor growth and progression; molecular mechanisms underlying the functional crosstalk between estrogens, androgens, and growth factors in breast cancer; regulation of aromatase enzyme activity in the male gonad and in breast cancer cell lines
As Guest Editors of the Journal Cells (IF 7,666), we have the privilege to invite you to contribute a review or original article to the Special Issue “Forkhead-box (Fox) O Family Transcription Factors in Cancer”.
Forkhead-box class O (FoxO) family members FoxO1a, FoxO3a, FoxO4, and FoxO6 are nuclear transcription factors that control diverse biological processes, affecting development, metabolism, stem cell maintenance, and longevity. They have also been increasingly recognized as tumor suppressors for their ability to regulate the expression of genes involved in cell proliferation, DNA repair, apoptosis, angiogenesis, cell migration, and metastasis. Thus, deregulation of FoxOs expression and function has been associated with cancer initiation, progression, and drug resistance. However, several other studies have shown that FoxOs might also promote tumor progression in certain circumstances.
Therefore, this SI is aimed at deepening the understanding on FoxOs regulation and functions in cancer as well as in normal tissues, in order to clarify their prognostic value in various subsets of tumors and, at the same time, pave the way to more effective treatment options, exploiting FoxOs as targetable factors in cancer therapy.
Dr. Catia Morelli
Prof. Marilena Lanzino
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- forkhead-box class O transcription factors
- tumor progression
- gene transcription
- drug resistance
- endocrine therapy